TransCode Therapeutics Statistics
Total Valuation
RNAZ has a market cap or net worth of $7.75 million. The enterprise value is -$10.07 million.
Important Dates
The last earnings date was Wednesday, April 15, 2026, after market close.
| Earnings Date | Apr 15, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
RNAZ has 916,968 shares outstanding. The number of shares has increased by 5,392.22% in one year.
| Current Share Class | 916,968 |
| Shares Outstanding | 916,968 |
| Shares Change (YoY) | +5,392.22% |
| Shares Change (QoQ) | +9.52% |
| Owned by Insiders (%) | 0.14% |
| Owned by Institutions (%) | 5.81% |
| Float | 832,425 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.75 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.29
| Current Ratio | 6.29 |
| Quick Ratio | 5.37 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2,900.98 |
Financial Efficiency
Return on equity (ROE) is -46.26% and return on invested capital (ROIC) is -16.00%.
| Return on Equity (ROE) | -46.26% |
| Return on Assets (ROA) | -14.14% |
| Return on Invested Capital (ROIC) | -16.00% |
| Return on Capital Employed (ROCE) | -12.08% |
| Weighted Average Cost of Capital (WACC) | 12.51% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.02M |
| Employee Count | 12 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, RNAZ has paid $226,068 in taxes.
| Income Tax | 226,068 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -3.89% in the last 52 weeks. The beta is 1.50, so RNAZ's price volatility has been higher than the market average.
| Beta (5Y) | 1.50 |
| 52-Week Price Change | -3.89% |
| 50-Day Moving Average | 9.18 |
| 200-Day Moving Average | 9.94 |
| Relative Strength Index (RSI) | 43.77 |
| Average Volume (20 Days) | 5,727 |
Short Selling Information
The latest short interest is 41,071, so 4.48% of the outstanding shares have been sold short.
| Short Interest | 41,071 |
| Short Previous Month | 49,976 |
| Short % of Shares Out | 4.48% |
| Short % of Float | 4.93% |
| Short Ratio (days to cover) | 5.50 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -19.19M |
| Pretax Income | -34.44M |
| Net Income | -36.27M |
| EBITDA | -19.12M |
| EBIT | -19.19M |
| Earnings Per Share (EPS) | -$52.59 |
Full Income StatementBalance Sheet
The company has $17.81 million in cash and n/a in debt, giving a net cash position of $17.81 million or $19.43 per share.
| Cash & Cash Equivalents | 17.81M |
| Total Debt | n/a |
| Net Cash | 17.81M |
| Net Cash Per Share | $19.43 |
| Equity (Book Value) | 151.88M |
| Book Value Per Share | 11.27 |
| Working Capital | 18.49M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$19.52 million and capital expenditures -$6,660, giving a free cash flow of -$19.52 million.
| Operating Cash Flow | -19.52M |
| Capital Expenditures | -6,660 |
| Depreciation & Amortization | 76,446 |
| Net Borrowing | n/a |
| Free Cash Flow | -19.52M |
| FCF Per Share | -$21.29 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |